Ignite Creation Date:
2024-05-06 @ 8:07 AM
Last Modification Date:
2024-10-26 @ 11:56 AM
Study NCT ID:
NCT02678533
Status:
COMPLETED
Last Update Posted:
2021-12-22
First Post:
2016-02-05
Brief Title:
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Pilot Study Assessing the Feasibility of CD34 Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FancoMob
Brief Summary:
The purpose of this study is to assess the feasibility of Plerixafor used in combination with G-CSF Granulocyte Colony Stimulating Factor in 5 Fanconi anemia patients to mobilize and collect a sufficient number of peripheral blood CD34 cells for peripheral blood apheresis for further gene therapy study
Detailed Description:
Fanconi anemia is an autosomal recessive disease with an average survival of around 24 years old The number of cells producted by bone marrow decreases around 5-10 years old Hematological symptoms occur around 7 years old 80 of patients with Fanconi anemia have clinical signs of bone marrow failure in the first decade of life Generally macrocytosis is the first noticeable sign Then it leads to thrombocytopenia anemia and pancytopenia
Epidemiologic studies show that nearly all of the patients will have medullar aplasia before 40 years old which is then the first cause of mortality
It must be emphasized that these complications may occur simultaneously for the same patient so joint therapeutic intervention is needed
There is no basic treatment Some currently used treatments cure cytopenias These treatments involve blood transfusion oral androgen hematopoietic growth factor administration such as Epo and G-CSF to treat anemia and neutropenia These treatments are not curative Hematopoietic stem cell transplantation is the only treatment able to restore permanently hematopoiesis However this treatment leads to a high level risk of developing solid tumors and other complications
All these data justify of developing a stem cells gene therapy treatment using a lentiviral vector expressing wild-type FANCA gene under CIBER promoter
Three studies have shown the potential number of cells to be mobilized in patients with Fanconi anemia
The aim is first to show if administering G-CSF with plerixafor may lead to collect enough cells to potentially perform a gene therapy graft Secondly the study will assess the tolerance the stem cells mobilization kinetic and collected cells biological features
This study will be performed in Necker Children Hospital 8 patients will be enrolled in order to reach 5 treated patients and to analyse how many injections and days are required to reach the cells number goal
Sequential blood samples of patients will be drawn to monitor complete blood count CBC platelet CD34 cells rate and stem cells phenotype
The clinical and biological data will be anonymously entered in a electronic case report by the investigators up to the end of the study
Epidemiologic studies show that nearly all of the patients will have medullar aplasia before 40 years old which is then the first cause of mortality
It must be emphasized that these complications may occur simultaneously for the same patient so joint therapeutic intervention is needed
There is no basic treatment Some currently used treatments cure cytopenias These treatments involve blood transfusion oral androgen hematopoietic growth factor administration such as Epo and G-CSF to treat anemia and neutropenia These treatments are not curative Hematopoietic stem cell transplantation is the only treatment able to restore permanently hematopoiesis However this treatment leads to a high level risk of developing solid tumors and other complications
All these data justify of developing a stem cells gene therapy treatment using a lentiviral vector expressing wild-type FANCA gene under CIBER promoter
Three studies have shown the potential number of cells to be mobilized in patients with Fanconi anemia
The aim is first to show if administering G-CSF with plerixafor may lead to collect enough cells to potentially perform a gene therapy graft Secondly the study will assess the tolerance the stem cells mobilization kinetic and collected cells biological features
This study will be performed in Necker Children Hospital 8 patients will be enrolled in order to reach 5 treated patients and to analyse how many injections and days are required to reach the cells number goal
Sequential blood samples of patients will be drawn to monitor complete blood count CBC platelet CD34 cells rate and stem cells phenotype
The clinical and biological data will be anonymously entered in a electronic case report by the investigators up to the end of the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-005264-14 | EUDRACT_NUMBER | None | None |